BGM Group Ltd.
About BGM Group Ltd.
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $25.1M
- Net income
- -$1.4M
- Total assets
- $53.0M
- Market cap
- $58.4M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $58.4M
- Shares outstanding
- 182.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 12, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $1.4M in FY2024.
- Trading 98% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BGM Group Ltd..
Write a review
News about BGM Group Ltd.
News & sentiment via Polygon.io
